You are here: vision-research.eu » News » Newsdetails:

UK gene therapy company raises funding for retinal disease treatment

UK gene therapy company – Gyroscope Therapeutics Ltd – raises £50.4 million funding for retinal disease treatment

Gyroscope Therapeutics Ltd., based in Stevenage, UK, has announced the successful completion of a £50.4 million investment to advance clinical development of an investigational gene therapy treatment for dry age-related macular degeneration (dry-AMD).

Funding Research Health Business

Related Links